BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.76% | 75.20% | -176.85% | 260.87% | 45.26% |
| Total Depreciation and Amortization | -115.97% | -32.39% | 6.67% | -90.73% | 111.79% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 602.00% | -- |
| Total Other Non-Cash Items | -82.73% | -162.38% | 121.27% | -17.12% | -389.14% |
| Change in Net Operating Assets | 144.63% | -109.47% | 464.52% | -25.12% | 88.06% |
| Cash from Operations | -51.95% | -1,089.83% | 93.17% | 69.91% | 12.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -200.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.47% | 199.17% | 54.57% | -173.33% | 9.59% |
| Cash from Investing | -109.18% | 199.16% | 54.70% | -173.29% | 9.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.32% | -0.08% | -0.64% | 89.70% | -1,065.99% |
| Issuance of Common Stock | -100.00% | -88.10% | -73.29% | -2.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -36.68% | -157.18% | -83.05% | 952.12% | 8.95% |
| Foreign Exchange rate Adjustments | 68.92% | -82.87% | 626.83% | -150.62% | 100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -743.31% | 139.25% | -31.93% | -187.50% | 303.30% |